Product
Arimoclomol
6 clinical trials
7 indications
Indication
Amyotrophic lateral sclerosisIndication
Gaucher's DiseaseIndication
Type 1Indication
Type IIIIndication
IBMIndication
Niemann-Pick DiseaseIndication
Type CClinical trial
Open Label, Non-randomized Extension Trial to Assess Long Term Safety and Efficacy of Arimoclomol in Subjects With Amyotropic Lateral Sclerosis Who Have Completed the ORARIALS-01 TrialStatus: Terminated, Estimated PCD: 2021-07-02
Clinical trial
A Phase 3, Randomised, Placebo-Controlled Trial of Arimoclomol in Amyotropic Lateral SclerosisStatus: Completed, Estimated PCD: 2020-12-18
Clinical trial
Multicentre Double-blinded, Randomized Placebo-controlled Study of Arimoclomol in Patients Diagnosed With Gaucher Disease Type 1 or 3Status: Terminated, Estimated PCD: 2020-04-01
Clinical trial
An Open-label, Non-randomized Trial to Investigate the Efficacy and Safety of Early Versus Delayed Start of Arimoclomol in Patients With Sporadic Inclusion Body Myositis Who Have Completed the IBM4809 TrialStatus: Terminated, Estimated PCD: 2021-11-15
Clinical trial
Early Access Program With Arimoclomol for the Treatment of Niemann-Pick Disease Type C in the USStatus:
Clinical trial
Phase II Study of Arimoclomol for the Treatment of Sporadic Inclusion Body Myositis (IBM)Status: Completed, Estimated PCD: 2021-01-11